Three-year-old Abeona Therapeutics is poised to enter the clinic with its lead gene therapy programs targeting some devastating lysosomal diseases.
In collaboration with patient advocate groups, researchers and clinicians, Abeona President and CEO Tim Miller tells Informa Pharma Insights global...





